A randomized, double‐blind phase 1b study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of the NLRP3 inhibitor selnoflast in patients with moderate to severe active ulcerative colitis

BACKGROUND: The NLRP3 inflammasome drives release of pro‐inflammatory cytokines including interleukin (IL)‐1β and IL‐18 and is a potential target for ulcerative colitis (UC). Selnoflast (RO7486967) is an orally active, potent, selective and reversible small molecule NLRP3 inhibitor. We conducted a r...

Descripción completa

Detalles Bibliográficos
Autores principales: Klughammer, Barbara, Piali, Luca, Nica, Alexandra, Nagel, Sandra, Bailey, Lorna, Jochum, Christoph, Ignatenko, Stanislav, Bläuer, Angela, Danilin, Sabrina, Gulati, Pratiksha, Hayward, Joanne, Scepanovic, Petar, Zhang, Jitao David, Bhosale, Satish, Chong, Chui Fung, Christ, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10644327/
https://www.ncbi.nlm.nih.gov/pubmed/37962000
http://dx.doi.org/10.1002/ctm2.1471

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10644327/
https://www.ncbi.nlm.nih.gov/pubmed/37962000
http://dx.doi.org/10.1002/ctm2.1471

Ejemplares similares